Vanguard Capital Management’s Relay Therapeutics RLAY Stock Holding History
Bought
Maintained
Sold
Other funds holding RLAY
Vanguard Capital Management's RLAY Position: Q3 2026 in Review
Vanguard Capital Management increased its Relay Therapeutics (RLAY) stake by 0.53% in Q3 2026, buying an estimated $910K and bringing the position to 9,011,920 shares worth $163M. The position accounts for ﹤0.01% of the portfolio, ranked #1235.
Vanguard Capital Management first reported a position in RLAY in Q1 2026 and has held it in 3 quarters since. The position peaked at $168M in Q2 2026. 261 funds tracked by Wall St. Rank hold RLAY as of Q3 2026.
- Vanguard Capital Management held 9,011,920 shares of Relay Therapeutics worth $163M as of Q3 2026.
- Vanguard Capital Management bought 47,497 Relay Therapeutics shares in Q3 2026, an estimated $910K.
- Relay Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #1235 holding.
- Vanguard Capital Management first reported a position in Relay Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Capital Management's Relay Therapeutics position peaked at $168M in Q2 2026.
- 261 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2026.
Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.